Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HMPL-A83 in advanced malignant neoplasm
NCT05429008Phase 1Completed
- Sponsor
- HUTCHMED
- Start
- Jul 2022
- Primary completion
- Apr 2025
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of HMPL-A83 in solid tumor, lymphoma, acute myeloid leukemia (AML) and 1 more, sponsored by HUTCHMED. Primary endpoints: Safety information/AE, SAE up to 3 years, Maximum Tolerated Dose up to 2 years and 1 more. Started Jul 2022; status: completed.
02
Drugs
HMPL-A83
03
Conditions
solid tumorlymphomaacute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT05429008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05429008.